Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Atorvastatin + telmisartan is a fixed-dose combination drug used to treat patients with both high blood pressure (hypertension) and high cholesterol (dyslipidemia). Atorvastatin is a statin that inhibits HMG-CoA reductase to reduce cholesterol synthesis in the liver and lower LDL cholesterol and triglycerides while raising HDL cholesterol. Telmisartan is an angiotensin II receptor blocker (ARB) that blocks the action of angiotensin II on vascular smooth muscle and adrenal gland AT1 receptors. This leads to vasodilation and reduced blood pressure. The combination lowers cardiovascular risk by addressing two major risk factors—hypertension and hypercholesterolemia—simultaneously[1][4]. Clinical studies show this combination improves lipid profiles and blood pressure control in patients with comorbid conditions such as obesity or non-alcoholic fatty liver disease[4].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on atorvastatin + telmisartan.